Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
atezolizumab + cobimetinib
- Development stage
- Unknown
- Lead developer
- Genentech
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Atezolizumab + cobimetinib is an investigational combination therapy consisting of atezolizumab, a monoclonal antibody targeting programmed death-ligand 1 (PD-L1), and cobimetinib, a small molecule inhibitor of mitogen-activated protein kinase kinase (MEK). Atezolizumab acts as an immune checkpoint inhibitor by blocking PD-L1 and enhancing T-cell–mediated antitumor responses. Cobimetinib inhibits MEK1/2 in the MAPK pathway, suppressing tumor cell proliferation and survival. The combination aims to enhance tumor immunogenicity while directly inhibiting oncogenic signaling pathways. This regimen has been studied in advanced solid tumors including biliary tract cancer and melanoma[2][3][4][5].
- Brand names
- Cotellic (cobimetinib)Tecentriq (atezolizumab)
- Other names
- cobimetinib + atezolizumab
02
Targets
MEK1 (Dual specificity mitogen-activated protein kinase kinase 1)CD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on atezolizumab + cobimetinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on atezolizumab + cobimetinib.